The NICE has issued final draft guidance endorsing the use of CSL Vifor's Filspari (sparsentan) for primary IgA nephropathy.

An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea ...

Aptar Digital Health has signed a licensing agreement with AstraZeneca for detecting CKD using the latter’s AI-driven ...

In combination with Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib) and anti-oestrogen drug Faslodex (fulvestrant), Itovebi ...

GSK has received approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab).

Genentech has announced an investment exceeding $700m to establish its first East Coast manufacturing facility in North ...

Artificial Intelligence (AI) is now used throughout clinical trials, from recruitment to analysis – but are regulators ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Eli Lilly and Company has received marketing authorisation from the Australian Therapeutic Goods Administration (TGA) for ...

The rise of GLP-1 agonist therapies has transformed obesity treatment, delivering unprecedented results and revealing their ...

Experts predict growing pains as the life sciences sector moves to adapt to the EU AI Act. The EU Artificial Intelligence (AI ...